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Objective: To investigate the use and interpretation of spirometry in primary care (PC) in
the diagnosis of chronic obstructive pulmonary disease (COPD) and to identify the
treatment schedules administered.
Methods: An observational study was performed in a randomized sample of 251 PC
physicians including 2130 patients with COPD. Data on the performance of spirometry and
the results and the treatment administered were collected as were sociodemographic and
clinical data.
Results: Spirometric results were obtained in 1243 (58.4%). Most (1118/1243; 89.9%)
corresponded to FEV1 (%) values with a mean of 57% (SD ¼ 21.5%). It is of note that only
31.8% of spirometric results provided post-bonchodilator results, and 42.9% and 43.1% of
the spirometries presented not plausible FVC or FEV1 values, respectively. Treatment
varied greatly, with more than 3 drugs being prescribed in 30.6% of the cases. Long-acting
beta-2 agonists and inhaled corticosteroids were prescribed in more than 50% of the
patients. Tiotropium was administered in 32.4%. According to the GOLD guidelines, 22.8%
of the patients in GOLD II, 50% in III and 66.7% in IV were receiving incorrect treatment.
Conclusions: Only 58.4% of the cases included had undergone spirometry. Important
deﬁciencies were observed in the interpretation of the results of spirometry. These
difﬁculties may inﬂuence the low implementation of treatment guidelines in COPD in PC.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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M. Miravitlles et al.1754Introduction normal clinical practice of PC physicians in patients withChronic obstructive pulmonary disease (COPD) is an im-
portant public healthcare problem throughout the world.
Despite anti-smoking campaigns, the prevalence and mor-
tality rate of COPD continues rising every year.1 In 2020 it is
calculated that COPD will be the ﬁfth cause of disability and
the third cause of death.2
A previous epidemiologic study demonstrated the pre-
valence of COPD in the general Spanish population between
40 and 70 years of age to be of 9.1%.3 However, more
importantly, it was observed that 78% of the patients
identiﬁed with COPD were not diagnosed, and among those
who were 60% were not being treated according to the
current guidelines.3,4 Primary care (PC) physicians have a
privileged setting for detecting early bronchial obstruction
and initiating anti-smoking counseling and pharmacologic
treatment. Different studies have demonstrated that
screening for COPD with the use of spirometry in PC is
possible and provides high diagnostic performance.5–10 In
addition to the diagnosis, spirometry allows the patient to
be classiﬁed according to disease severity and treatment
may be adjusted following international guidelines.2 It is
important to identify the deﬁciencies in the undertaking and
interpretation of spirometry in PC to thereby design
strategies aimed at providing better care to chronic
respiratory patients. Moreover, knowing the more common
patterns of prescribing makes it possible to elaborate
training programs to adapt treatment to the current
guidelines.
A representative group of PC physicians was asked to
participate in an observational study with the aim of
determining the index of spirometric procedures per-
formed in patients with COPD and their level of interpreta-
tion by PC physicians. The use of medication in these
patients and its adaptation to international guidelines was
also evaluated.Method
The aim of the present study was to ascertain the normal
practice of PC physicians in the diagnosis and treatment of
patients with COPD. Physicians in PC from all the autonomous
communities in Spain were randomly selected from a
database of the sponsoring companies and were invited to
participate in the study. The physicians who refused to
participate were substituted by other randomly selected
colleagues. This project is part of a more extensive
educational program, which included the resolution of
clinical cases which investigated the diagnostic attitudes
versus hypothetical cases of patients with COPD of both
sexes11 and the completion of questionnaires on the problems
relating the use of spirometry in normal everyday practice.12
The participating physicians were asked to collect data
from the ﬁrst 10 patients with COPD attending their clinic
from November 2003 to April 2004 with a non-probabilistic
sampling of consecutive cases. They were advised to include
patients over 40 years of age, smokers or ex-smokers of at
least 10 pack years, diagnosed with COPD according to GOLD
criterion of a demonstration of a post-bronchodilator FEV1/
FVCo70%.2 Since the main objective was to determine theCOPD, including the use and interpretation of spirometry in
the diagnosis of these patients, analysis of all the cases
considered to have COPD according to the physician and even
cases without spirometric results or with incorrect results was
accepted. The exclusion criteria were: patients diagnosed
with bronchial asthma, clinically signiﬁcant bronchiectasia,
cystic ﬁbrosis or other severe pulmonary diseases.
Information was obtained regarding the sociodemo-
graphic characteristics, comorbidity, smoking habits, years
of evolution and symptoms of COPD, severity of obstruction
by spirometry, results of bronchodilator tests, treatment in
the stable phase, antiinﬂuenza and antipneumococcal
vaccination and treatment of exacerbations.
Due to the design of the study, we were unable to check
the quality of spirometries performed by the participants.
To obtain a gross estimate of the level of understanding and/
or interpretation of the spirometries by the participating
physicians, plausible intervals were deﬁned for FVC between
700 and 6000ml and FEV1 between 500 and 5000ml. No
previous selection of the participants according to access to
spirometry was done. Furthermore, no spirometer was
provided to the participants and no speciﬁc instructions
regarding spirometry were given, in order not to interfere
with normal clinical practice.
Adherence of treatment to guidelines was evaluated
according to the GOLD guidelines2 in those patients who
could be classiﬁed in severity stages by providing plausible
spirometric results. Incorrect treatment was considered to
be: (1) COPD with symptoms and without inhaled bronch-
odilator treatment (beta-2 agonists or anticholinergics), (2)
patients treated with inhaled corticosteroids (IC) and FEV1
450% or with less than two exacerbations within the
previous year. Although the GOLD guidelines recommend
treatment with IC in patients with severe obstruction who
also present at least two exacerbations within the previous
year, less restrictive criteria were used on considering this
treatment correct in patients with two or more previous
exacerbations independently of the degree of obstruction,
(3) patients receiving theophylline treatment not taking
beta-2 agonists or anticholinergetics, or (4) patients with
COPD under treatment with continuous oral corticosteroids.
Statistical analysis
The baseline characteristics of the patients were described
using frequency tables for the nominal variables and
measurements of central trends and dispersion for the
continuous variables.
Analysis of the relationship between variables in the cases
in which this was observed was performed with the chi-
square test. Continuous variables were analyzed using the
Student’s t-test in cases of normal distribution of the
variable, otherwise non-parametric tests were used.
Results
Population
Two hundred and ﬁfty-one PC physicians belonging to the 17
autonomous communities in Spain participated in the study
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Spirometry and treatment of COPD 1755with the distribution being proportional to the number of
physicians within each community. Data were received from
a total of 2130 patients with a mean participation per
investigator of 8.5 cases (SD ¼ 2.6). The characteristics of
the patients included both globally and classiﬁed according
to severity are shown in Table 1.Characteristics of COPD
The mean duration of COPD was 12.4 years (SD ¼ 8.8 years).
All the patients included were smokers or ex-smokers with a
total of 1474 (63.8%) active smokers. The mean tobacco
consumption in both groups was of 45.8 pack years
(SD ¼ 29.3 pack years) with no signiﬁcant differences based
on disease severity being observed (p ¼ 0.16).
Cough, expectoration and dyspnea were reported in 44.2%
of the patients while only 0.9% did not have any chronic
respiratory symptom. The percentage of patients with 3 of
the symptoms cited increased signiﬁcantly as severity of
COPD measured by FEV1 (%) also increased (Table 1).Table 1 Characteristics of COPD patients included in the stud
COPD (N ¼ 2130) Global (N ¼ 2130) With FEV1 (%) N ¼
FEV1o30% (N ¼ 84
Sex: males [N (%)] 1733 (81.4) 82 (97.6)
Mean age (SD) 69.1 (10.6) 69.6 (8)
Work activity: no [N (%)] 1778 (83.4) 79 (94)
Associated diseases
Yes 1844 (86.6) 76 (90.5)
1 535 (14.9) 20 (23.8)
2 548 (25.7) 23 (27.4)
3 370 (17.4) 16 (19.1)
43 360 (16.9) 17 (20.2)
Pack-years. Mean (SD) 45.8 (29.3) 54.7 (38.8)
Years evolution COPD 12.4 (8.8) 14.7 (9.6)
Mean (SD)
Symptoms
Cough 1590 (74.6) 57 (67.8)
Expectoration 1250 (58.7) 47 (55.9)
Dyspnea 1826 (85.7) 81 (96.4)
Number of symptoms
0 18 (0.9) 0
1 500 (23.5) 24 (28.6)
2 670 (31.5) 19 (22.6)
3 942 (44.2) 41 (48.8)
Parameters last 12 months
Exacerbations 2.4 (3.1) 3.56 (2.7)
Emergency dpt. visit 1.3 (2.5) 2.6 (3.2)
Medical visits 4.5 (4.9) 5.7 (4.8)
Hospital admission. 0.53 (1.2) 1.5 (2.4)
Days admitted 3.72 (8.5) 10.1 (14.7)
ICU admission 0.11 (2.4) 1.6 (11.9)The mean number of exacerbations in the previous year
was of 2.4 (SD ¼ 3.1) but the mean number of hospital
admissions was only 0.5 (SD ¼ 1.2). The most severe
patients demonstrated a greater frequency of medical care
required compared with moderate and mild patients
(po0.0001 in all the comparisons) (Table 1).
Diagnosis by spirometry
Spirometric results were only provided in 1243 (58.4%) of
the patients. The most frequent value was FEV1 (%) in 1118
cases (1118/1243; 89.9%) with a mean value of 57%
(SD ¼ 21.5%). Of these cases, 84 (7.5%) had a FEV1 o30%,
350 (31.3%) between 30% and 50% and 684 (61.2%) showed
FEV1450%. The proportion of spirometric results considered
not plausible was of 42.9% for FVC and 43.1% for FEV1
(Fig. 1). The bronchodilator test was carried out in 688 patients
(32.3%) and in 32.1% of the cases the physician considered it
to be positive, but only 2.3% fulﬁlled the post-bronchodi-
lator FEV1 criteria 4200ml compared to the baseline value
and 412% of the pre-bronchodilator value.y.
1118 p
) FEV1 30–50% (N ¼ 350) FEV1 450% (N ¼ 684)
313 (89.4) 560 (81.9) o0.001
70.3 (9.8) 67.2 (10.7) o00001
315 (90) 513 (75) o0.0001
296 (84.6) 566 (82.7) 0.689
83 (23.7) 164 (23.9)
100 (28.6) 180 (26.3)
63 (18) 111 (16.2)
50 (14.3) 111 (16.2)
48.4 (31.8) 43.1 (25.1) 0.177
12.8 (8.4) 10.8 (7.8) o0.0001
249 (71.1) 504 (73.7) 0.818
206 (58.8) 396 (57.9) 0.212
321 (91.7) 557 (81.4) o0.0001
2 (0.6) 10 (1.5) o0.05
88 (25.1) 164 (23.9)
92 (26.3) 237 (34.6)
168 (48) 273 (39.9)
2.5 (2.1) 2.05 (2.1) o0.0001
1.5 (2.3) 0.81 (1.8) o0.0001
4.9 (4.9) 3.69 (3.7) o0.0001
0.7 (1.3) 0.31 (0.9) o0.0001
4.9 (10.7) 2.30 (6.8) o0.0001
0.03 (0.2) 0.05 (0.6) o0.0001
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M. Miravitlles et al.1756Usual pharmacologic treatment
The patterns of prescribing varied greatly. In 5.2% of the
cases no treatment was prescribed and in 30.6% more than
three drugs were indicated, with the number of drugs
increasing according to the severity of the disease
(po0.0001) (Table 2). Antipneumococcal vaccination was
prescribed to 34% of patients and antiinﬂuenza vaccination
to 63.8%.
The short- and long-acting beta-2 agonists (SABAs and
LABAs) and ICs were used in more than 50% of the patients,
with this proportion surpassing 70% in patients with an FEV1
less than 30%. Short- and long-acting anticholinergics were
used in 32.1% and 32.4% of the cases, respectively (Table 3).
The use of mucolytic drugs (26.9%) was of note in the oral
treatment, being signiﬁcantly greater in the group of
patients in whom spirometry was not available versus those
in whom it was (31.8% versus 23.4%; po0.0001). The second
most commonly used oral drug was theophylline (15.3%),
being signiﬁcantly more frequently used in the group ofFigure 1 Quality of spirometric values provided by the
investigators out of a total of 1243 procedures reported. Values
considered plausible: FVC between 700 and 6000ml; FEV1
between 500 and 5000ml.
Table 2 Distribution of drugs used for treatment of COPD.
Total (N ¼ 2130) N (%) Patients with FEV1
FEV1o30% (N ¼ 84
Number of drugs
0 110 (5.1) 1 (1.2%)
1 252 (11.8) 2 (2.4%)
2 564 (26.4) 11 (13.1%)
3 553 (25.9) 23 (27.4%)
43 651 (30.6) 47 (55.9%)
Mean number of drugs (SD) 2130 (100) 3.75 (1.4)
Incorrect treatment 1118 (52.4) 56 (66.7%)
Incorrect treatment according to GOLD guidelines can only be evpatients with an FEV1 o30% (Table 3). The most frequent
combinations were the LABAs plus ICs (39.9%) compared
with LABAs plus tiotropium bromide without ICs in only 5.2%
of the patients. Table 4 shows the comparison of treatment
according to the availability of plausible FEV1 values (ml).
Patients with FEV1 values (ml) out of range received fewer
drugs (a mean of 2.6 versus 3.1; po0.001) and were
signiﬁcantly less likely to receive ipratropium, LABAs and
ICs.
Adherence of pharmacologic treatment to the GOLD
guidelines was evaluated in patients in whom spirometry
was available. According to the previously deﬁned criteria,
the percentage of patients receiving treatment not con-
sistent with guidelines ranged from 22.8% in patients with
GOLD stage II, 50% in GOLD III and a maximum of 66.7% in
GOLD IV, with the differences being statistically signiﬁcant
(po0.0001).
The most frequent patterns of treatment are shown in
Table 5. The patients who received ICs as the only treatment
were younger and with more preserved pulmonary function.
There was also a lower proportion of active smokers in this
group. No signiﬁcant differences were observed among the
patients receiving a combination of LABAs and ICs and those
treated with tiotropium bromide.
Among the patients receiving combined treatment with
the two groups of long duration bronchodilators (LABAs and
tiotropium), those not also receiving ICs had a milder
disease and thus, presented fewer exacerbations in the
previous year (mean of 2.3 exacerbations versus 3.4;
po0.001), had a lower rate of active smokers (67.6% versus
94.1%; po0.001) and presented more preserved pulmonary
function compared with patients administered ICs.Discussion
The results of the present study have demonstrated that a
large proportion of patients considered as having COPD in PC
have been diagnosed on the basis of clinical criteria without
spirometric conﬁrmation. The spirometric values provided
were considered not plausible in as much as 43% of cases for
FEV1. Only 32.3% of spirometries were completed with a
bronchodilator test, but almost all cases considered positive(%) (N ¼ 1118) p
) FEV1 30–50% (N ¼ 350) FEV1 450% (N ¼ 684)
17 (4.9%) 40 (5.8%) 0.001
21 (6%) 97 (14.2%)
84 (24%) 206 (30.1%)
95 (27.1%) 183 (26.7%)
133 (38%) 158 (23.1%)
3.11 (1.4) 2.6 (1.3) 0.001
175 (50%) 156 (22.8%) 0.001
aluated in patients with FEV1 (%) values.
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Table 3 Oral and inhaled treatment administered to patients with COPD according to the spirometric results.
All
N ¼ 2130
No spirometry
N ¼ 887
Spirometry available
All
N ¼ 1243
FEV1o30%
N ¼ 84
FEV1 30–50%
N ¼ 350
FEV1 450%
N ¼ 684
Oral treatment
Theophyllines 327
(15.3%)
141 (15.9%) 186
(14.9%)
26 (30.9%) 65 (18.6%) 74 (10.8%)(4)
Oral betaadrenergics 65 (3.1%) 41 (4.6%) 24 (1.9%) 2 (2.4%) 5 (1.4%) 12 (1.7%)
Mucolytics 573
(26.9%)
282 (31.8%) 291
(23.4%)
25 (29.8%) 82 (23.4%) 148 (21.6%)
Continuous oral
corticosteroids
113 (5.3%) 51 (5.7%) 62 (4.9%) 14 (16.7%) 26 (7.4%) 18 (2.6%)(4)
Inhaled treatment
Short-acting beta-2
agonists
1178
(55.3%)
499 (56.3%) 679
(54.6%)
60 (71.4%) 205 (58.6%) 354 (51.7%) (1)
Long-acting beta-2 agonists 1188
(55.7%)
468 (52.7%) 723
(58.2%)
62 (73.8%) 221 (63.1%) 381 (55.7%) (2)
Ipratropium 683
(32.1%)
272 (30.7%)y 411
(33.1%)
35 (41.7%) 122 (34.9%) 215 (31.4%)
Tiotropium 690
(32.3%)
289 (32.6%) 401
(32.3%)
31 (36.9%) 138 (39.4%) 202 (29.5%) (3)
Inhaled corticosteroids 1191
(55.9%)
489 (55.1%) 702
(56.5%)
60 (71.4%) 223 (63.7%) 352 (51.4%) (4)
ySpirometry versus no spirometry; p ¼ 0.022, Differences in the three groups of severity: (1) p ¼ 0.0035; (2) p ¼ 0.0010; (3)
p ¼ 0.0043; (4) po0.0001.
Spirometry versus no spirometry, po0.0001.
Table 4 Treatment administered to patients with COPD according to the availability of correct values of FEV1 (ml).
Treatment Patients with FEV1 (ml) (N ¼ 735) P value
Plausible FEV1 (ml) (N ¼ 199) Out of range FEV1 (ml) (N ¼ 536)
SABAs 60.2 53.4 0.63
LABAs 70.2 54.3 0.01
Ipratropium 43.4 29.4 o0.001
Tiotropium 27.8 31.9 0.13
Ics 60.1 56.6 o0.001
Theophyllines 22.6 12.5 0.40
Mucolytics 23.3 21.7 0.27
Ocs 9.1 4.5 o0.001
Mean number of drugs (SD) 3.1 (1.3) 2.6 (1.42) o0.001
Values in percentages, except otherwise speciﬁed.
SABAs ¼ short-acting beta-2 agonists; LABAs ¼ long-acting beta-2 agonists; ICcs ¼ inhaled corticosteroids; OCs ¼ oral corticosteroids.
Spirometry and treatment of COPD 1757by the physician did not fullﬁl reversibility criteria. Of the
patients included, 95% were following some treatment for
their respiratory disease and the number of drugs prescribed
increased signiﬁcantly with the severity of the disease. The
treatment administered did not comply with the guidelines
in a high proportion of the cases, ranging from 22.8% of
GOLD II patients and 66.7% of GOLD IV patients.
Despite spirometry and bronchodilator test are required
for the diagnosis of COPD, only 58% of the patients includedpresented spirometric data and of them, only 32.3% had
post-bronchodilator results. Moreover, in many cases the
data collected were not within the intervals considered as
plausible, particularly for FEV1 and FVC. Nonetheless, since
the main objective was to investigate the everyday clinical
practice of PC physicians in patients with COPD, with special
attention being given to the use and interpretation of
spirometry, all the cases with this diagnosis, according to
the attending physician, were accepted for analysis.
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Table 5 Characteristics of the patients according to the treatment schedules prescribed.
Tiotropium
bromide
(N ¼ 690)
LABAs+ICs
(N ¼ 849)
Only ICs
(N ¼ 15)
Tiotropium
+LABAs+ICs
(N ¼ 326)
Tiotropium+LABAs
(without ICs)
(N ¼ 111)
Mean age (SD) 69 (9.7) 70 (10.0) 62 (9.0) 69 (9.5) 71 (8.7)
Sex, % males 593 (86.4%) 694 (82.3%) 11 (73.3%) 271 (87.0%) 98 (88.3%)
Mean no (SD) associated
diseases and distribution
2.2 (1.6) 2.3 (1.6) 1.4 (1.1) 2.47 (1.7) 2.0 (1.3)
0 81 (11.7%) 96 (11.3%) 3 (20.0%) 36 (11.0%) 12 (10.8%)
1 163 (23.6%) 187 (22.0%) 5 (33.3%) 70 (21.5%) 30 (27.0%)
2 193 (28.0%) 222 (26.1%) 6 (40.0%) 82 (25.1%) 35 (31.5%)
3 132 (19.1%) 175 (20.6%) 0 (0%) 69 (21.2%) 20 (18.0%)
43 121 (17.5%) 169 (19.9%) 1 (6.7%) 69 (21.2%) 14 (12.6%)
Mean (SD) FEV1 (%) 53.1 (16.5) 52.0 (16.9) 63.5 (12.9) 49.2 (15.9) 56.4 (17.7)
Current smoker* (%) 463 (67.1%) 518 (61.0%) 7 (46.7%) 209 (94.1%) 75 (67.6%) *
Mean (SD) packs/year 49.2 (28.9) 48.6 (31.7) 33.2 (29.7) 51.6 (30.4) 47.2 (27.5)
Mean (SD) years of
evolution
12.7 (8.7) 13.2 (8.8) 7.0 (3.8) 13.6 (8.9) 12.7 (9.0)
Mean (SD) no.
exacerbations in previous
year
2.9 (3.7) 2.7 (3.4) 0.8 (0.8) 3.4 (4.8) 2.3 (1.7) *
Cough (%) 519 (75.0%) 639 (75.3%) 10 (66.7%) 253 (77.6%) 83 (74.8%)
Expectoration (%) 438 (63.5%) 510 (60.1%) 7 (46.7%) 209 (64.1%) 74 (66.7%)
Dyspnea (%) 636 (92.2%) 771 (90.8%) 10 (66.7%) 311 (95.4%) 97 (87.4%)
LABAs ¼ long-acting beta-2 agonists; ICcs ¼ inhaled corticosteroids.
Tiotropium+LABAs+ICs versus tiotropium+LABAs (without ICs).
*po0.001.
M. Miravitlles et al.1758However, it should be pointed out that some of the patients
included in the study may not have had COPD, but rather
had been classiﬁed and treated as such by the participating
investigators.
The IBERPOC study demonstrated that only 28% of the
patients detected in the community with COPD were
diagnosed.4 Other studies performed in different countries
have also shown a high level of underdiagnosis of COPD.13–15
The ﬁrst contact of the patient with the healthcare system is
usually through PC consultation. Therefore, it is important
for these physicians to have easy access to spirometry and
correct formation as to its management and interpretation.
Several studies have evaluated the utility of screening
programs for COPD in PC and have demonstrated high yield
in the early detection of patients with this disease.5–10
Similar results were found in a previous study undertaken
in Spain in which as much as 61.6% of the patients with COPD
included by PC physicians did not undergo spirometry and an
additional 9.1% had spirometric values not compatible with
COPD.16 In another study carried out by PC physicians in
Italy, 61.8% of the cases included with the supposed
diagnosis of COPD had normal spirometry.17 The quality of
spirometry in PC should be carefully monitored to avoid
erroneous diagnosis.18 With adequate formation there is no
reason for not being able to achieve precise, reliable
measurements in this healthcare setting.19 It should also
be taken into account that physicians must have important
motivation to perform spirometry. In the abovementioned
Italian study, it was found that the number of spirometric
procedures performed by the participating physicians in aprogram of ofﬁce spirometry decreased considerably over
the period of the study and the percentage of physicians
who considered spirometry as a useful tool also diminished
over time.17
Regarding the interpretation of spirometry, except for the
FEV1 (%) values, the remaining parameters provided showed
great dispersion and a high percentage of the values were
outside the intervals considered as plausible. Thus, the only
value considered for classifying the patients by severity was
the FEV1 (%). Interpretation of the spirometric results is
crucial; they inﬂuence in the decisions of treatment of
patients by PC physicians.20–22 However, with respect to the
diagnosis of COPD, in a previous study it was found that
many PC physicians did not consider this diagnosis when
spirometry demonstrated mild or moderate obstruction and
only severe obstruction was accepted as diagnostic of
COPD.11 This means that the efﬁcacy of the screening
programs of COPD in PC will be very low if COPD is not
diagnosed in individuals in the initial stages of the disease.
On analyzing the treatments administered, it was found
that 26% of the patients received 3 drugs for their
respiratory disease and 30.6% were taking more than 3. In
a similar study performed in patients controlled by
respiratory specialists, with a mean FEV1 (%) of 49.7%, 64%
of the patients received 3 or more drugs.23 This is important
because of the elevated costs implicated,24 but also because
a higher number of drugs received has been independently
associated with a greater alteration in the quality of life of
the patients with COPD.23,25 In regard to the groups of drugs
administered, a greater proportion of LABAs were used
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Spirometry and treatment of COPD 1759compared to long-duration anticholinergics, although tio-
tropium had only recently been launched at the time of this
study. Other studies have reported that the prescription of
LABAs is more frequent by PC physicians than by pneumol-
ogists, contrary to what occurs with anticholinergics.26
Consistently, in another study performed in France, it was
found that the prescription of anticholinergics signiﬁ-
cantly increased following consultation with a respiratory
physician.27
The use of ICs is recommended in patients with stages III
and IV presenting frequent exacerbations.2 Table 6 shows
the percentage of the use of different drugs, among them
the ICs, in some studies from 1997 to 2006.23–34 According to
our data, 51.4% of the stage II patients received ICs. Other
studies have also demonstrated their use in more than 50%
of the patients with FEV1 (%) 450% demonstrating scarce
compliance with the guidelines.26,27
The high prescription of mucolytic drugs is of note,
particularly in patients in whom spirometry had not been
performed. In previous studies carried out in PC, mucolytics
were also widely used in COPD, especially in patients
without spirometry28 and in the most severe stages of the
disease.27 This also demonstrates the scarce compliance
with the guidelines.2 Theophyllines were used in 30.9% of
stage IV patients. The use of theophyllines has fallen over
time following the appearance of inhaled anti-inﬂammatory
medication, basically the Ics.28 In recent studies, the use of
theophyllines is not even mentioned since these drugs have
been difﬁcult to ﬁnd in pharmacies in recent years.30,31
In summary, this study has demonstrated the high
percentage of patients with COPD treated by PC physicians
without spirometric and bronchodilator test. On many
occasions, the spirometric data are erroneous or subject
to problems of interpretation. Our results show that often
the treatment prescribed is not consistent with the current
guidelines. Important formative actions are required on the
diagnosis and treatment of COPD among the collective of PC
physicians.References
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